Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Esoteric testing is the examination of 'uncommon' particles or substances. It isn't performed in a routine clinical research facility. These tests are performed when there is prerequisite of extra data outside routine lab testing, for legitimate conclusion of disease, set up a forecast or select and administer a restorative treatment. This testing requires skilled people to perform out the test and investigate the outcomes because of utilization of refined synthetic compounds and instruments. The tests are performed by specific and autonomous clinical reference research facilities attributable to staggering expense. The tests are controlled by stringent regulatory framework. These tests are not performed consistently.
Rapidly enhancing healthcare segment in developing nations alongside rising number of complex research facilities offering propelled services will support industry development. Growing number of baby boomers prone to suffer from several chronic conditions will act as high impacting factor for industry growth. Developing interest for proteomics and genomics combined with increasing investment towards improvement of innovative test solutions for recognizing uncommon substances in the body will impel business development. The forecast and assessment of treatment response, development of pharmaceutical ventures and rising predominance of endless infections has raised interest for customized genomics human services arrangements. However, stringent regulations and shortage of skilled professionals in developing nations will limit industry development over the estimate time span.
The global esoteric testing market is segmented based on type, technology and region.
Based on type, the market is further segmented into genetics, endocrinology, immunology, molecular diagnostics, microbiology, oncology, serology, and toxicology. Molecular diagnostics is the fastest developing fragment of the market, trailed by the immunology and oncology portions, inferable from rising predominance of uncommon and hereditary diseases and appeal for customized prescription treatment.
By technology, this market is categorized into chemiluminescence, ELISA, mass spectrometry, real time PCR and flow cytometry. Chemiluminescence business section commanded esoteric testing market in 2017 and is foreseen to witness development attributable to high appropriation of chemiluminescence in this testing because of its high productivity alongside need of small sample.
Geographically, the global esoteric testing market is divided in North America, Europe, Asia Pacific and Rest of the World. North America rules the esoteric testing market, trailed by Europe, because of higher frequency and commonness rate, developing awareness about early disease recognition, and quick appropriation of refined instruments. U.S. esoteric testing market represented around 35% of the worldwide business share in 2017. Rising pervasiveness of rare and complex illnesses alongside progressions in restorative research will drive U.S. esoteric testing market over the coming years.
Major players operating in the esoteric testing market include Laboratory Corporation of America Holdings, OPKO Health, Inc., ARUP Laboratories, Genomic Health, Inc., Quest Diagnostics, American Medical Laboratories, Gold Standard Diagnostics Corp, and ZeptoMetrix Corporation.
The global esoteric testing market is classified by type, technology and geography. By type, the market is segmented into genetics, endocrinology, immunology, molecular diagnostics, microbiology, oncology, serology, and toxicology. Immunology portion represented around 28% piece of the share in 2017 due to the high predominance of infectious diseases combined with high demand for advanced molecular tests. Accessibility of immunology laboratory administrations for each restorative claim to fame will decidedly affect fragment development within a reasonable time-frame. Comprehensively, rising awareness regarding early disease diagnosis and treatment combined with rising frequencies of cancer will drive oncology fragment growth over the forecast period. By technology, the global esoteric testing market is categorised into chemiluminescence, ELISA, mass spectrometry, real time PCR and flow cytometry. ELISA business fragment held more than 20% of business share in 2017 and will witness a rapid development from 2019 to 2024. Besides, ELISA is regular method for fundamental research, high throughput screening performed in labs, and medication discovery program. New advancements in biomarker field prompting accessibility of new targets will create revenue growth for the fragment. The market is studied across the countries of North America, Europe, Asia-Pacific and Rest of the World. Asia Pacific is a developing business sector for this testing because of growing commonness of sickness, slow improvement of medicinal foundation, rising awareness, and critical patient pool with neglected therapeutic needs. However, high expense, absence of accessibility of prepared faculty, and poor patient mindfulness are factors limiting the esoteric testing market in locales, such as, Middle East and Africa and Latin America. The various companies involved in this market are Laboratory Corporation of America Holdings, OPKO Health, Inc., ARUP Laboratories, Genomic Health, Inc., Quest Diagnostics, American Medical Laboratories, Gold Standard Diagnostics Corp, and ZeptoMetrix Corporation.
Why to buy this report:
